Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Swiss Exchange  >  Cosmo Pharmaceuticals N.V.    COPN   NL0011832936

COSMO PHARMACEUTICALS N.V.

(COPN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector news

Cosmo and RedHill Biopharma to Expand Strategic Partnership with Exclusive Licensing and Manufacturing Agreement for Multiple Products

08/13/2020 | 01:05am EST

Cosmo and RedHill Biopharma to Expand Strategic Partnership with Exclusive Licensing and Manufacturing Agreement for Multiple Products

Dublin, Ireland - 13 August 2020: Cosmo Pharmaceuticals NV (SIX: COPN) today announced that that it has entered into a binding term sheet with RedHill Biopharma (Nasdaq: RDHL), a specialty biopharmaceutical company ("RedHill"), with respect to an exclusive licensing and manufacturing agreement for multiple products. The transaction is expected to close in the coming weeks.


Pursuant to the agreement, the companies will co-develop a novel next-generation therapy for the eradication of H. pylori infection. Cosmo is to receive the exclusive European rights to the new drug. Cosmo will pay RedHill $7 million upon signing of the license agreement, an additional $2 million upon approval in Europe and 30% royalties. The companies plan to jointly execute clinical trials pursuing simultaneous regulatory approvals in the US and Europe with a cost split of 70% RedHill and 30% Cosmo.


Cosmo will become the exclusive worldwide manufacturer with respect to: a) the novel next-generation therapy for the eradication of H. pylori infection; b) Movantik® (naloxegol)[i], which RedHill recently acquired from AstraZeneca, and c) RHB-204 for pulmonary nontuberculous mycobacteria (NTM) infections. Cosmo will be paid €5.5 million for tech transfer, formulation and development work in respect of these products.


Additionally, Cosmo will finance the planned pivotal Phase 3 clinical study with RHB-204, which recently received FDA clearance to proceed, with a payment of $5 million upon signing of the agreement and an additional $7 million in two milestone payments. Cosmo will be entitled to 15% royalty payments.


Alessandro Della Chà, Cosmo's CEO, said: "We are happy we have found new ways to expand our relationship with our partner RedHill and now we are eager to start working on these multiple opportunities for the benefit of both companies. With these deals we will simultaneously develop a new next-generation product for H. pylori eradication, expand our manufacturing franchise and help RedHill accelerate the clinical development of RHB-204".


Dror Ben-Asher, RedHill's CEO, said: "We are very pleased to expand our strategic partnership with Cosmo Pharmaceuticals and accelerate the planned pivotal Phase 3 study with RHB-204 in pulmonary NTM infections and the development of a next-generation H. pylori treatment. Importantly, Cosmo has a proven track record of formulating, developing and manufacturing novel therapies for multiple countries thus ensuring high quality supply."

[i] Full prescribing information for Movantik® (naloxegol) is available at: www.Movantik.com


About Cosmo Pharmaceuticals

Cosmo is a specialty pharmaceutical company focused on developing and commercialising products to treat selected gastrointestinal disorders and improve endoscopy quality measures through aiding the detection of colonic lesions. Cosmo has also developed medical devices for endoscopy and has recently entered into a partnership with Medtronic for the global distribution of GI Genius™ its artificial intelligence device for use in coloscopies and GI procedures. Cosmo has licensed Aemcolo™ to Red Hill Biopharma and is the licensee of BYFAVO™ (Remimazolam) for the US for procedural sedation, which it has sub-licensed to Acacia. For additional information on Cosmo and its products please visit the Company's website: www.cosmopharma.com

Financial calendar

Investora, Zurich September 23, 2020

Contact

Niall Donnelly, CFO & Head of Investor Relations

Cosmo Pharmaceuticals N.V.

Tel: +353 1 817 03 70

ndonnelly@cosmopharma.com




Provider
Channel
Contact
EQS Group Ltd., Switzerland
switzerland.eqs.com


newsbox.ch
www.newsbox.ch


Provider/Channel related enquiries
cs.switzerland@eqs.com
+41 41 763 00 50
All news about COSMO PHARMACEUTICALS N.V.
12/01Cosmo Pharmaceuticals appoints new Chief Medical Officer
TE
12/01Cosmo Pharmaceuticals ernennt neuen Chief Medical Officer
TE
11/24COSMO PHARMACEUTICALS N : Announces Senior Leadership Changes
AQ
11/23Cosmo Pharmaceuticals Announces Senior Leadership Changes
TE
11/23Cosmo Pharmaceuticals kündigt Wechsel im Führungsteam an
TE
11/20COSMO PHARMACEUTICALS N : announces expansion of agreement with Dr. Falk Pharma ..
AQ
11/19Cosmo Pharmaceuticals announces expansion of agreement with Dr. Falk Pharma f..
TE
11/18COSMO PHARMACEUTICALS N : announces approval of Eleview in Japan
AQ
11/17Cosmo Pharmaceuticals announces approval of Eleview® in Japan
TE
10/12COSMO PHARMACEUTICALS N : Acacia Pharma completes drawdown from EUR25 million lo..
AQ
More news
Financials
Sales 2020 53,1 M 64,1 M 64,1 M
Net income 2020 -8,53 M -10,3 M -10,3 M
Net cash 2020 51,0 M 61,5 M 61,5 M
P/E ratio 2020 -132x
Yield 2020 -
Capitalization 1 125 M 1 356 M 1 357 M
EV / Sales 2020 20,2x
EV / Sales 2021 16,7x
Nbr of Employees 261
Free-Float 45,8%
Chart COSMO PHARMACEUTICALS N.V.
Duration : Period :
Cosmo Pharmaceuticals N.V. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends COSMO PHARMACEUTICALS N.V.
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 4
Average target price 102,69 €
Last Close Price 77,77 €
Spread / Highest target 43,1%
Spread / Average Target 32,0%
Spread / Lowest Target 21,3%
EPS Revisions
Managers
NameTitle
Alessandro E. Della Chà Chief Executive Officer & Executive Director
Mauro Severino Ajani Executive Chairman
Giuseppe Cipriano Chief Operating Officer
Niall Donnelly Chief Financial Officer & Head-Investor Relations
Davide Malavasi Director-Qualified Person & Technical
Sector and Competitors
1st jan.Capitalization (M$)
COSMO PHARMACEUTICALS N.V.10.17%1 356
JOHNSON & JOHNSON-0.82%380 876
ROCHE HOLDING AG-4.76%282 467
PFIZER, INC.3.21%212 942
NOVARTIS AG-10.48%206 479
MERCK & CO., INC.-11.61%203 389